Lancet Rheumatology

Article	Citations
Real-world evidence for prehospital COVID-19 treatment in systemic autoimmune rheumatic disease	1542
Research in Brief	1315
Brachial plexopathy: an unusual manifestation of Takayasu arteritis	517
Can contextual factors improve clarity of the results from clinical trials of low back pain?	326
A disseminated gonococcal infection with spinal locations	229
Biological disease-modification in axial spondyloarthritis: insights from MRI	195
Thrombotic microangiopathy as a presentation of anti-synthetase syndrome	107
Molecular signature-based decision making in the era of targeted therapies for systemic lupus erythematosus	96
Women in rheumatology in Africa	93
Dual JAK and ROCK inhibition with CPL'116 in patients with rheumatoid arthritis with inadequate response to methotrexate: a randomised, double-blind, placebo-controlled, phase 2 trial	92
Reigniting the burnt-out health-care workforce	91
Three-dimensional, in-vitro approaches for modelling soft-tissue joint diseases	88
Post-COVID condition in patients with inflammatory rheumatic diseases: a prospective cohort study in the Netherlands	87
CAR T-cell therapy in autoimmune diseases: where are we and where are we going?	82
Associations of improvement in laboratory tests with clinical outcomes in patients with active systemic lupus erythematosus: a multinational longitudinal cohort study	74
1-year results of treatment with rituximab in polymyalgia rheumatica: an extension study of a randomised double-blind placebo-controlled trial	73
Patient involvement in digital rheumatology: lessons from practice	72
Pathways driving tendinopathy and enthesitis: siblings or distant cousins in musculoskeletal medicine?	69
Anti-tumour necrosis factor therapy for early-stage Dupuytren's disease (RIDD): a phase 2b, randomised, double-blind, placebo-controlled trial	67
Research in Brief	65
Outdoor temperatures and Raynaud's phenomenon in patients with systemic sclerosis	61
Assessing glucocorticoid toxicity: are the measures sensitive enough?	60
Correction to Lancet Rheumatol 2026; 8: e5–6	57
First-line biological versus conventional synthetic disease-modifying antirheumatic drug therapy in adult-onset Still's disease: a multicentre, retrospective, propensity weighted cohort study	56
Sex-related differences in patient characteristics, and efficacy and safety of advanced therapies in randomised clinical trials in psoriatic arthritis: a systematic literature review and meta-analysis	53

Biosimilars and the era of interchangeability	53
Preload deficiency as a treatable cause of fatigue and exercise intolerance in SLE	52
Early-stage Dupuytren's disease treatment; a promising next step?	51
Interleukin-5 inhibition in eosinophilic granulomatosis with polyangiitis: time for another approach?	47
Proof-of-concept studies in axial spondyloarthritis: there are no shortcuts	46
Four SARS-CoV-2 vaccine doses or hybrid immunity in patients on immunosuppressive therapies: a Norwegian cohort study	45
Artificial intelligence and high-dimensional technologies in the theragnosis of systemic lupus erythematosus	45
The association of outdoor temperature and self-reported Raynaud's phenomenon severity among people with systemic sclerosis: a Scleroderma Patient-centered Intervention Network Cohort study	44
Reclassifying ANCA-associated vasculitis: a focus on kidney disease	44
Addition of aerobic physical activity to resistance exercise for hip osteoarthritis (PHOENIX): a randomised comparative effectiveness trial	43
Baricitinib and ruxolitinib use through the UK HLH Network	43
Pain in clinical trials for knee osteoarthritis: estimation of regression to the mean	43
Additional SARS-CoV-2 vaccine doses: a little is better than none	43
Sex as a predictor of clinical phenotype and determinant of immune response in IgG4-related disease: a retrospective study of patients fulfilling the American College of Rheumatology–European League A	43
Environmental and societal factors associated with COVID-19-related death in people with rheumatic disease: an observational study	43
ANCA-associated large and small vessel vasculitis with aorto-pulmonary-renal syndrome	41
Clinical hypnosis and pain management in sharp debridement of skin ulcers in immune-mediated inflammatory diseases	39
Research in Brief	39
Optimal non-opioid analgesic combinations after total hip arthroplasty – Authors' reply	38
Constitutional symptoms of severe childhood-onset polyarteritis nodosa	37
Urgent reform needed for homecare medicines services	36
Clinical trial design: time to accelerate the pace of change?	36
Kanon Jatuworapruk: bringing out the enjoyment in life	35
Let's talk about sex in interstitial lung disease	35
Correction to Lancet Rheumatol 2025; 7: e851–63	34
Global access to biological disease-modifying drugs	33
Fetal and maternal outcome in the pregnancies of patients with systemic sclerosis and very early diagnosis of systemic sclerosis in France: a prospective study	33
Tackling heterogeneity in Sjögren's disease	33
Effectiveness and persistence of biological and targeted synthetic treatment in patients with rheumatoid arthritis and chronic kidney disease: a multicentre, prospective cohort study	32
Development of a diagnostic prediction model for giant cell arteritis by sequential application of Southend Giant Cell Arteritis Probability Score and ultrasonography: a prospective multicentre study	32
The 2024 US election—voting for equitable health care	32
Abatacept in early polymyalgia rheumatica (ALORS): a proof-of-concept, randomised, placebo-controlled, parallel-group trial	32
Explanation for substandard of care comparators in rheumatology randomised trial protocols	31
Advancing research and equity through collaboration	31
Are we ready for home spirometry for systemic sclerosis-associated ILD?	31
Digital self-management for back pain in the UK	31
Pneumococcal vaccine in adults with immune-mediated inflammatory diseases	31
Sex differences of brain oscillatory activity and quantitative sensory testing in people with chronic osteoarthritis pain: a cross-sectional study	30
Outcomes with and without outpatient SARS-CoV-2 treatment for patients with COVID-19 and systemic autoimmune rheumatic diseases: a retrospective cohort study	30
Suspending methotrexate for 2 weeks after COVID-19 vaccination	30
Better diagnostic tools needed for biopsy-negative giant cell arteritis	30
Can we prevent the onset of rheumatoid arthritis in patients with high-risk features?	30
Research in Brief	30
Correction to Lancet Rheumatol 2025; published online Feb 27. https://doi.org/10.1016/S2665-9913(24)00348-5	30
Challenges in the therapeutic management of psoriatic arthritis	29
JIA care under the microscope	29
Development and validation of an OMERACT ultrasound scoring system for the extent of calcium pyrophosphate crystal deposition at the joint level and patient level	29
Factors associated with biological and targeted synthetic disease-modifying antirheumatic drug initiation for rheumatoid arthritis in underserved patient groups in England and Wales, UK: a national co	29
Safety and tolerability of nintedanib in patients with interstitial lung diseases in subgroups by sex: a post-hoc analysis of pooled data from four randomised controlled trials	29
Intra-articular botulinum toxin A injection for painful base-of-thumb osteoarthritis: a double-blind, randomised, controlled, phase 3 trial (RHIBOT)	28

Enabling and supporting public and patient involvement in arthritis research	28
Correction to Lancet Rheumatol 2026; 8: e265–73	27
Stratification in systemic sclerosis according to autoantibody status versus skin involvement: a study of the prospective EUSTAR cohort	27
For SLE activity and glucocorticoids: aim low	27
Cranial involvement in giant cell arteritis	27
Microscopic polyangiitis presenting with retinal frosted branch angiitis	26
Coronary polyarteritis nodosa	25
Beneficial side-effects of colchicine for patients with gout	25
Reconciling immunotherapy and autoimmunity: not for the faint of heart	25
Refining strategies for biological and targeted synthetic DMARD initiation in rheumatoid arthritis – Authors' reply	25
Sex-related differences in health-care use in adult patients with inflammatory arthritis in Ontario, Canada: a population-based cohort study	24
COP27 Climate Change Conference: urgent action needed for Africa and the world	24
Polychondritis in a child	24
Penélope Palominos: rheumatology by sight and touch	24
The impact of COVID-19 on care of early inflammatory arthritis in the UK	24
Gout in central Asia: a few things make a big difference	24
Jean Liew: from Bronte scholar to social media influencer	24
Pain and wellbeing in young people with arthritis	23
Effectiveness of pneumococcal vaccination in adults with common immune-mediated inflammatory diseases in the UK: a case–control study	23
Factors associated with resolution of ultrasound subclinical synovitis in anti-CCP-positive individuals with musculoskeletal symptoms: a UK prospective cohort study	23
Vascular Ehlers-Danlos syndrome: a heritable condition with potentially fatal consequences	23
Sex and gender impact on achievement of remission in people with rheumatoid arthritis in Switzerland: a cohort study	23
Safety and efficacy of rituximab in systemic sclerosis (DESIRES): open-label extension of a double-blind, investigators-initiated, randomised, placebo-controlled trial	23
Systemic sclerosis and pregnancy: advancing prospective evidence for risk stratification and postpartum care	23
Top priorities for prehabilitation in orthopaedics	22
Advancing predictive accuracy for shoulder replacement surgery	22
How long do revised and multiply revised hip replacements last? A retrospective observational study of the National Joint Registry	22
Coronary polyarteritis nodosa in a young adult	22
Serum type I interferon score as a disease activity biomarker in patients with diffuse cutaneous systemic sclerosis: a retrospective cohort study	22
Treatment modalities of marginal zone lymphoma and overall survival, haematological response, and underlying Sjögren's disease activity: a multicentre, retrospective, observational study	22
Occupational therapist-led versus rheumatologist-led care in people with hand osteoarthritis in Norway: an open-label, multicentre, randomised controlled, non-inferiority trial	21
Ustekinumab with or without methotrexate for psoriatic arthritis?	20
Time to revisit the therapeutic benefits of exercise for osteoarthritis?	20
Prize trends in rheumatology: the Gender Award Gap	20
Role of plasma exchange in ANCA-associated vasculitis – Authors' reply	20
Correction to Lancet Rheumatol 2023; 5: e461–73	20
Effectiveness of a fourth mRNA dose among individuals with systemic autoimmune rheumatic diseases during the Omicron era	19
DAVIX: a vascular outcome measure in systemic sclerosis	19
Research in Brief	19
Rheumatology congresses post COVID-19: we cannot regress	19
Cognitive impairment in individuals with rheumatic diseases: the role of systemic inflammation, immunomodulatory medications, and comorbidities	18
Lupus low disease activity state and remission and risk of mortality in patients with systemic lupus erythematosus: a prospective, multinational, longitudinal cohort study	18
Substantiation of trophoblast transport of maternal anti-SSA/Ro autoantibodies in fetuses with rapidly progressive cardiac injury: implications for neonatal Fc receptor blockade	18
Vasculitis management remains a challenge during pregnancy	18
Association of nirmatrelvir–ritonavir with post-acute sequelae and mortality among patients who are immunocompromised with COVID-19 in Hong Kong: a retrospective cohort study	18
Pregnant pause in women with rheumatoid arthritis	18
Digital remote monitoring in rheumatology: using health economics to support wider adoption	18
Prevention of psoriatic arthritis: the next frontier	17
Global, regional, and national burden of other musculoskeletal disorders, 1990–2020, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021	17
Palliative care in patients with rheumatic diseases	17
Withholding methotrexate after vaccination with ChAdOx1 nCov19 in patients with rheumatoid or psoriatic arthritis in India (MIVAC I and II): results of two, parallel, assessor-masked, randomised contr	16
Correction to Lancet Rheumatol 2022; 4: e177–87	16
The same genotype gives rise to a spectrum of disorders	16
Correction to Lancet Rheumatol 2022; 4: e853–63	16
Susac syndrome: challenges of interpreting treatment data in a rare disease	16
Psoriatic arthritis: strategy shaping treatment	16
Diffuse alveolar haemorrhage during pregnancy in systemic lupus erythematosus	15
The influence of safety warnings on the prescribing of JAK inhibitors	15
Research in Brief	15
Vasculitis: the promising road ahead	15
Research in Brief	15
Cardiovascular risk in gout: time for action	15
Debate over interventional procedures for chronic spine pain	15
Research in Brief	15
Safety and efficacy of mirikizumab versus secukinumab and placebo in the treatment of moderate-to-severe plaque psoriasis (OASIS-2): a phase 3, multicentre, randomised, double-blind study	15
Forging ahead on fibromyalgia	14
Rheumatic cognitive impairment: a new clinical entity?	14
Disease-associated brain activation predicts clinical response to TNF inhibition in rheumatoid arthritis (PreCePra): a randomised, multicentre, double-blind, placebo-controlled phase 3 study	14
Calcium pyrophosphate deposition disease	14
Time to talk to adults with rheumatic diseases about herpes zoster vaccination	14
Herpes zoster vaccination and flares in rheumatic diseases	14
Repurposing leflunomide and hydroxychloroquine to treat Sjögren's disease (RepurpSS-II): a randomised, double-blind, placebo-controlled, phase 2b trial	14
Progressive bone destruction of the hand in Gorham–Stout disease	14
Beyond very early systemic sclerosis: deciphering pre‑scleroderma and its trajectories to open new avenues for preventive medicine	14
Interosseous tendon inflammation in the hands of patients with clinically suspect arthralgia: analysis of MRI data from a prospective cohort study	14
Cardiovascular risk factor control in antiphospholipid syndrome, and differences between primary and systemic lupus erythematosus-related antiphospholipid syndrome (SURF-SLE and APS project): a cross-	14
CD19-targeting CAR T-cell therapy in patients with diffuse systemic sclerosis: a case series	14
Predictors of pregnancy outcomes in SLE	14
Local immune effector cell-associated toxicity syndrome in CAR T-cell treated patients with refractory systemic lupus erythematosus – Authors' reply	13
Aspirin desensitisation in pregnant individuals with autoimmune disease	13

Michael Barrett: navigating hostile terrain	13
Predictors of pregnancy outcomes in SLE	13
Narendra Kumar Bagri: taking paediatric rheumatology in India to new heights	13
Promise and challenges of mesenchymal stromal cell therapy in severe SLE	13
Characterisation of a high-risk profile for maternal thrombotic and severe haemorrhagic complications in pregnant women with antiphospholipid syndrome in France (GR2): a multicentre, prospective, obse	13
Differentiating biologics to prevent psoriatic arthritis in patients with psoriasis	13
Getting better at quantifying the toxicity of glucocorticoids	13
Serum biomarkers associated with baricitinib response in patients with juvenile idiopathic arthritis: a post-hoc analysis of the phase 3 JUVE-BASIS trial	13
Proton pump inhibitors in systemic sclerosis: a reappraisal to optimise treatment of gastro-oesophageal reflux disease	12
Safety of CAR T-cell therapy for cancer in pre-existing autoimmune or inflammatory disease: a retrospective comparative cohort study	12
Moderators of the effect of therapeutic exercise for knee and hip osteoarthritis: a systematic review and individual participant data meta-analysis	12
Global, regional, and national burden of low back pain, 1990–2020, its attributable risk factors, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021	12
Modelling allopurinol-induced severe adverse cutaneous reactions	12
Identifying key health system components associated with improved outcomes to inform the re-configuration of services for adults with rare autoimmune rheumatic diseases: a mixed-methods study	12
Challenges of designing and conducting cohort studies and clinical trials in populations of pregnant people	12
Pregnancy outcomes in women with primary Sjögren's syndrome: an analysis of data from the multicentre, prospective, GR2 study	12
Preclinical or subclinical rheumatoid arthritis-associated interstitial lung disease: misleading terms with potentially deleterious consequences	12
Integrated analysis of dermal blister fluid proteomics and genome-wide skin gene expression in systemic sclerosis: an observational study	12
An imaging crisis in axial spondyloarthritis	12
Association of sustained lupus low disease activity state with improved outcomes in systemic lupus erythematosus: a multinational prospective cohort study	12
Effect of a 2-week interruption in methotrexate treatment on COVID-19 vaccine response in people with immune-mediated inflammatory diseases (VROOM study): a randomised, open label, superiority trial	12
Contesting the BACPAP consortium's consensus – Authors' reply	11
Research in Brief	11
Kimberly Templeton: creative change maker	11
Coronary polyarteritis nodosa in a young adult – Authors' reply	11
Long COVID in inflammatory rheumatic diseases—what's in a name?	11
Inclusion of pregnant populations in clinical trials in China: the ethical considerations	11
Including refractory systemic sclerosis-associated GAVE in research agendas	11
Debashish Danda	11
Early screening for rheumatoid arthritis-associated interstitial lung disease: statistical nuances challenge the role of disease activity – Authors' reply	10
Immunosuppression and SARS-CoV-2 breakthrough infections	10
Barriers to CAR T-cell therapy in rheumatology	10
Research in Brief	10
Long-term treatment transition patterns after intensive treatment strategies in early psoriatic arthritis: insights from the GOLMePsA clinical trial	10
Dual JAK and ROCK inhibition and comorbidities in rheumatoid arthritis	10
Risk loci involved in giant cell arteritis susceptibility: a genome-wide association study	10
Correction to Lancet Rheumatol 2022; 4: e262–73	10
Physician Global Assessment International Standardisation COnsensus in Systemic Lupus Erythematosus: the PISCOS study	10
The stark reality of living with arthritis in the UK	10
Efficacy and safety of branebrutinib (BMS-986195), an irreversible Bruton's tyrosine kinase inhibitor, for the treatment of rheumatoid arthritis: a phase 2a, randomised, double-blind, placebo-controll	9
Synovial tissue for personalised medicine in rheumatoid arthritis: hype or hope?	9
When the game changes: efficacy of rituximab in systemic sclerosis	9
Methotrexate plus ustekinumab versus ustekinumab monotherapy in patients with active psoriatic arthritis (MUST): a randomised, multicentre, placebo-controlled, phase 3b, non-inferiority trial	9
Risk-based stratified primary care for common musculoskeletal pain presentations (STarT MSK): a cluster-randomised, controlled trial	9
Diagnostic, research, and real-life effect of the 2023 EULAR−ACR classification criteria for antiphospholipid syndrome	9
Precision medicine in rheumatoid arthritis: unravelling sex-driven differences in response to treatment	9
The Gout by Dorian Haskard	9
Colchicum and gout: two millennia of therapeutic continuity	9
Research in Brief	9